



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : A61K 31/00	A2	(11) International Publication Number: WO 00/25766 (43) International Publication Date: 11 May 2000 (11.05.00)
(21) International Application Number: PCT/GB99/03536 (22) International Filing Date: 26 October 1999 (26.10.99) (30) Priority Data: 60/106,354 30 October 1998 (30.10.98) US (71) Applicant (for all designated States except US): ZENECA LIMITED [GB/GB]; 15 Stanhope Gate, London W1Y 6LN (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): LENGEL, David, John [US/US]; 1800 Concord Pike, P.O. Box 15437, Wilmington, DE 19850-5437 (US). RUMSEY, William, Leroy [US/US]; 1800 Concord Pike, P.O. Box 15437, Wilmington, DE 19850-5437 (US). (74) Agent: BRYANT, Tracey; Global Intellectual Property, AstraZeneca PLC, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: TREATMENT OF GASTRIC ASTHMA (57) Abstract Use of neurokinin 2 (NK2) receptor antagonists in the treatment or prevention of gastric asthma or adverse respiratory events associated with gastroesophageal reflux, including pharmaceutical compositions containing the NK2 receptor antagonist and methods for making such compositions.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

TREATMENT OF GASTRIC ASTHMA

Background

Gastric asthma, described by Bruno et al. (Int. J. IMPH. 10/3: 195-204, 1997; Mays, E.E. JAMA 236: 2626, 1976), is a syndrome arising from the gastroesophageal acid induced changes in respiratory function. There is a progressive body of evidence supporting the role of gastroesophageal reflux as a triggering factor of bronchial hyperreactivity leading to this syndrome.

The mammalian neurokinins comprise a class of peptide neurotransmitters which are found in the peripheral and central nervous systems. The three principal neurokinins are Substance P (SP), Neurokinin A (NKA) and Neurokinin B (NKB). There are also N-terminally extended forms of at least NKA. At least three receptor types are known for the three principal neurokinins. Based upon their relative selectivities favoring the neurokinin agonists SP, NKA and NKB, the receptors are classified as neurokinin 1 (NK1), neurokinin 2 (NK2) and neurokinin 3 (NK3) receptors, respectively. In the periphery, SP and NKA are localized in C-afferent sensory neurons, which neurons are characterized by non-myelinated nerve endings known as C-fibers, and are released by selective depolarization of these neurons, or selective stimulation of the C-fibers. C-Fibers are located in the airway epithelium, and the tachykinins are known to cause profound effects which clearly parallel many of the symptoms observed in asthmatics. The effects of release or introduction of tachykinins in mammalian airways include bronchoconstriction, increased microvascular permeability, vasodilation, increased mucus secretion and activation of mast cells. Thus, the tachykinins are implicated in the pathophysiology and airway hyperresponsiveness observed in asthmatics; and blockade of the action of released tachykinins may be useful in the treatment of asthma and related conditions.

Accordingly, NK2 antagonists have been implicated in the pathology of numerous diseases including asthma, airway oedema, bladder hypermotility, hypertension, pain, gastrointestinal-hypermotility, psychoses including schizophrenia and other psychiatric indications, such as depression and anxiety.

The development of antagonists for the NK2 receptor has been purported to be useful for treatment of bronchial reactivity (Barnes, P.J. Lancet, i: 242-245, 1986). Although the etiological relationship between gastroesophageal reflux and asthma is not clear, the number

of reflux episodes can be correlated to those of bronchial hyperreactivity (Vincent et al., Eur. Respir. J. 10/10: 2255-2259, 1997). Current asthma therapies have not been shown to reverse bronchial hyperreactivity and in some cases are associated with adverse side effects (steroids), the progressive diminution of the therapeutic benefits (beta agonists) and they have not been shown to have any beneficial effects for gastroesophageal reflux induced respiratory changes. Moreover, chronic asthma treatments such as theophylline and beta agonists may promote or worsen gastroesophageal reflux (Bruno et al., Int. J. IMPH. 10/3: 195-204, 1997). Therefore, there is an unmet medical need for a treatment that interrupts the cyclic nature of gastroesophageal reflux and asthma.

There are no suggestions that NK2 antagonists could be beneficial in treating gastric asthma and in particular in treating gastric asthma associated with gastroesophageal reflux, which is manifested in adverse respiratory events such as chronic cough and asthma. The use of NK2 antagonists minimises the possibility of side-effects associated with alternative methods of treating such disease conditions and offers the physician a valuable alternative treatment regime.

Summary of the Invention

The present invention relates to use of compounds that antagonise the pharmacological actions of the endogenous neurokinins, particularly at the NK2 receptor, and compositions containing them, in treating the aforementioned disease conditions and, in particular, gastric asthma.

Brief Description of the Drawings

The accompanying drawings incorporated in and forming part of the specification illustrates principles of the invention. In the drawings:

Figure 1 is a graph representing the effect of tachykinin antagonism on esophageal-acid-induced bronchoconstriction; and

Figure 2 is a graph representing the effect of Example 1 on HCl infusion into allergic Guinea pigs.

Description

The present invention provides a method of treating gastric asthma in a patient in need thereof with an effective amount of an NK2 receptor antagonist.

-3-

In another aspect the present invention provides a method of treating adverse respiratory events associated with gastroesophageal reflux in a patient in need thereof with an effective amount of an NK2 receptor antagonist.

In yet another aspect the present invention provides the use of an NK2 receptor antagonist in a method of manufacture of a medicament for the treatment of gastric asthma.


In yet another aspect the present invention provides the use of an NK2 receptor antagonist in a method of manufacture of a medicament for the treatment of treating adverse respiratory events associated with gastroesophageal reflux.

In yet a further aspect the present invention provides an NK2 receptor antagonist for use in the treatment of gastric asthma or for the treatment of treating adverse respiratory events associated with gastroesophageal reflux.

Compounds with NK2 receptor antagonist properties are known in the scientific and patent literature, for example in WO9719060, EPA739891, WO9624582, EPA709376, EPA709375, EPA680962, WO9516682, WO9515961, WO9512577, WO9505377, EPA630887, EPA625509, WO9314084, WO9605193, WO9422822 and many other patent applications.

Preferred NK2 receptor antagonists are SR-48968, SR-144190, YM-38336, MEN-10627, MEN-11420, GR-159897, RPR-106145, PD-147714, FK-224, MDL-105212A, MDL-105172A, L-743986, S-16474 (all reviewed by von Sprecher et al (IDrugs, 73 (1998)) and the compounds of WO9512577.

A particularly preferred compound is (S)-N-[2-(3,4-dichlorophenyl)-4-[4-(2-oxoperhydropyrimidin-1-yl)piperidino]butyl]-N-methyl-benzamide of the formula (I) or a pharmaceutically acceptable salt thereof, such as the dihydrochloride.



which is disclosed in WO9512577.

NK2 receptor antagonists may be prepared according to the references or by standard literature methods. It is well known in the art how to test a compound to assess whether it is an NK2 receptor antagonist, for example see assays in the aforementioned patent applications such as in WO9512577.

5 In order to use an NK2 antagonist for the therapeutic treatment of gastric asthma (including prophylactic treatment) of mammals including humans, it is normally formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition.

Therefore, in another aspect, the present invention provides a method of treating gastric asthma in a patient in need thereof with a pharmaceutical composition comprising an
10 effective amount of an NK2 receptor antagonist.

In a further aspect the present invention provides a pharmaceutical composition comprising an NK2 receptor antagonist for use in the treatment of gastric asthma.

Pharmaceutical compositions comprising an NK2 antagonist may be administered in standard manner, for example by oral, parenteral, buccal, nasal administration or by inhalation
15 or insufflation. For these purposes the compounds of this invention may be formulated by means known in the art into the form of, for example, tablets, capsules, aqueous or oily solutions, suspensions, emulsions, gels, nasal sprays, finely divided powders or aerosols or nebulisers for inhalation, and for parenteral use (including intravenous, intramuscular or infusion) sterile aqueous or oily solutions or suspensions or sterile emulsions.

20 The pharmaceutical composition comprising an NK2 antagonist may also contain, or be co-administered (simultaneously or sequentially) with, one or more pharmacological agents of value in treating gastric asthma or a related or associated disease.

The pharmaceutical composition will normally be administered to humans so that, for example, a daily dose of 0.01 to 25 mg/kg body weight (and preferably of 0.1 to 5 mg/kg body
25 weight) of compound is received. This daily dose may be given in divided doses as necessary, the precise amount of the compound received and the route of administration depending on the weight, age and sex of the patient being treated and on the particular disease condition being treated according to principles known in the art.

Typically, unit dosage forms will contain about 1 mg to 500 mg of a compound. For
30 example a tablet or capsule for oral administration may conveniently contain up to 250 mg (and typically 5 to 100 mg) of a compound. In another example, for administration by inhalation, a compound may be administered in a daily dosage range of 5 to 100 mg, in a

single dose or divided into two to four daily doses. In a further example, for administration by intravenous or intramuscular injection or infusion, a sterile solution or suspension containing up to 10% w/w (and typically 5% w/w) of a compound.

It has been demonstrated that tracheal plasma extravasation, a feature of asthma, induced by esophageal acid can be prevented by blockade of NK1 receptors (Hamamoto et al., J. Appl. Physiol. 82/3: 738-745, 1997). In a particular aspect therefore, treatment of gastric asthma with an NK2 receptor antagonist may be augmented with an NK1 receptor antagonist; alternatively, gastric asthma may be treated with a single compound containing dual antagonist activity against both receptors. Therefore, in one aspect an NK2 antagonist may be co-administered with an NK1 antagonist with the advantage of blocking both neurogenic inflammation (plasma extravasation, edema, and mucous secretion) and bronchial hyperreactivity. In another aspect the NK2 antagonist for use in this invention is also capable of antagonism at the NK1 receptors. That is, the compound for use in this invention is capable of antagonising the actions of both NK1 and NK2 receptors. Such compounds are known from the literature and may include compounds within the patent applications mentioned above as well as for example compounds within WO9610568, EPA733632, WO9637489, EPA699674, WO9722597, WO9628441, WO9827085, WO9834949, EPA776893, FRA2729952, FRA2729953, FRA2729954, WO9719926, WO9721680, WO9818761, WO9820010, WO28297, WO9634857, WO9634864, WO9639386, WO9827086, WO9714671, WO9898076694, WO9719942, WO9807722, WO9605193, WO9727188, WO9705110, EPA790248, EPA791592 and USP 5688960, 5696267, 5789422, 5691362, 5719147 and 5807865.

Therefore, in a further aspect, the present invention provides a method of treating gastric asthma in a patient in need thereof with an effective amount of an NK1/NK2 receptor antagonist.

In another aspect the present invention provides the use of an NK1/NK2 receptor antagonist in a method of manufacture of a medicament for the treatment of gastric asthma.

In yet a further aspect the present invention provides an NK1/NK2 receptor antagonist for use in the treatment of gastric asthma.

Gastroesophageal reflux, also known as heartburn, is a widespread disorder which affects millions of adults and children. Gastroesophageal reflux has been described as the retrograde movement of stomach contents into the esophagus. This is clearly discomforting.

If gastroesophageal reflux is not treated more severe disease conditions may occur such as esophagitis, ulceration, hemorrhage and related conditions. It has been estimated that approximately 40% of asthmatics suffer from gastroesophageal reflux. The aspiration of gastric contents into the airway or a vagal reflex arising from the esophagus may result in bronchoconstriction, as described by Harding and Richter, Chest. 111, 1359 (1997).

Gastroesophageal reflux is presently treated by antacids, histamine H₂-antagonists or proton pump inhibitors such as omeprazole. Relapse is common, regardless of therapy.

In another aspect the present invention provides an NK₂ receptor antagonist for treating gastroesophageal reflux and in particular for the treatment of the adverse respiratory events such as chronic cough and asthma associated with gastroesophageal reflux.

The present invention is illustrated by the tests and results hereinbelow.

NK₁ and NK₂ In Vivo Functional Assay

The activity of a compound as an antagonist of NK₁ and/or NK₂ receptors may be demonstrated in vivo in laboratory animals as described in: Buckner et al. "Differential Blockade by Tachykinin NK₁ and NK₂ Receptor Antagonists of Bronchoconstriction Induced by Direct-Acting Agonists and the Indirect-Acting Mimetics Capsaicin, Serotonin and 2-Methyl-Serotonin in the Anesthetized Guinea Pig." *J. Pharm. Exp. Ther.*, 1993, Vol 267(3), pp. 1168-1175. For experiments measuring the effects of infused acid into the esophagus on bronchoconstriction :

Compounds are tested in anesthetized guinea pigs pretreated with i.v. indomethacin (10 mg/kg, 20 min) and propranolol (0.5 mg/kg, 15 min). In some experiments thiorphan (10 mg/kg, 10 min), atropine (1 mg/kg, 25 min), 1-(α -(2-isopropoxyphenyl)aceto)-3-(4-phenylquinuclidin-1-yl)-3*R*-(3,4-dichlorophenyl)piperidine (1 μ mol/kg, 25 min), Example I (various doses, 30 min) or their combination are also administered i.v. Saline (pH 5.5) or HCl (pH 0-1) is infused (0.5 ml over 1 min) into the esophagus. The infusate is confined to the esophagus due to ligations at the proximal and distal ends. Pulmonary resistance (a measure of bronchoconstriction) is monitored for at least thirty minutes after cessation of the infusion. Peak resistance values during the monitored period are then determined and expressed as a percentage of the baseline pulmonary resistance before the esophageal infusion.

For experiments measuring the effects of infused acid into the esophagus on tracheal plasma extravasation (edema) :

-7-

Compounds are tested in anesthetized guinea pigs pretreated with i.v. 1-(α -(2-isopropoxyphenyl)aceto)-3-(4-phenylquinuclidin-1-yl)-3*R*-(3,4-dichlorophenyl)piperidine (3 μ mol/kg, 25 min) or its vehicle, atropine (1 mg/kg, 25 min) indomethacin (10 mg/kg, 20 min), propranolol (0.5 mg/kg, 15 min), HOE-140 (0.1 μ mol /kg, 12 min), thiorphan (10 mg/kg, 10 min) and Evans blue dye (30 mg/kg, 0 min). Saline (pH 5.5) or HCl (pH 0-1) is infused (0.5 ml over 1 min) into the esophagus. The infusate is confined to the esophagus due to ligations at the proximal and distal ends. Ten minutes following the esophageal infusion guinea pigs are perfused via the aorta (120 ml saline over 2 min) to remove intravascular dye. A section of trachea (1 cm) immediately caudal to the carina is removed, trimmed, weighed, and incubated in formamide for 18 hr at 60 ° C. The dye content of the tissue is then determined by measuring Absorbance, at 620 nm, of the resulting formamide/Evans blue solution and converting this value into ng Evans blue/mg trachea via a standard curve.

Results of testing of (S)-N-[2-(3,4-dichlorophenyl)-4-[4-(2-oxoperhydropyrimidin-1-yl)piperidino]butyl]-N-methyl-benzamide (formula (I)) are as follows. 1-(α -(2-isopropoxyphenyl)aceto)-3-(4-phenylquinuclidin-1-yl)-3*R*-(3,4-dichlorophenyl)piperidine is a known selective NK1 antagonist.

The graphs in Figures 1 and 2 clearly demonstrate that the NK2 receptor antagonist (Example I), either alone or in combination with the other treatments, is capable of completely inhibiting the increase in pulmonary resistance (i.e. bronchoconstriction) resulting from the infusion of 1 N HCl into the esophagus of guinea pigs (top graph). The muscarinic antagonist, atropine, or the NK1RA, 1-(α -(2-Isopropoxyphenyl)aceto)-3-(4-phenylquinuclidin-1-yl)-3*R*-(3,4-dichlorophenyl)piperidine, either alone or concomitantly have no effect on this increase in resistance (top graph). Even in an allergic, hyperreactive state (OA sensitized), as is often the case in asthma, NK2 receptor antagonism is able to antagonize the adverse pulmonary effects of infused acid (bottom graph). This experimental data is representative of the effects of acid reflux in the esophagus of human asthmatics suffering from "gastric asthma" and illustrates the anticipated benefit of NK2 receptor antagonists in treating this syndrome.

Examples

The following illustrates representative pharmaceutical dosage forms which may be used for the therapeutic or prophylactic administration of NK1 antagonists or pharmaceutically-acceptable salt or in vivo hydrolysable ester thereof hereinafter referred to as 'Compound X'):

-8-

	(i)	<u>Tablet 1</u>	<u>mg/tablet</u>
		'Compound X'	100.0
		Lactose	77.5
		Providone	15.0
5		Croscarmellose sodium	12.0
		Microcrystalline cellulose	92.5
		Magnesium stearate	<u>3.0</u>
			300.0
10	(ii)	<u>Tablet 2</u>	<u>mg/tablet</u>
		'Compound X'	20.0
		Microcrystalline cellulose	410.0
		Starch	50.0
		Sodium starch glycolate	15.0
15		Magnesium stearate	<u>5.0</u>
			500.0
	(iii)	<u>Capsule</u>	<u>mg/capsule</u>
		'Compound X'	5.9
20		Lactose	392.9
		Sodium lauryl sulphate	<u>1.2</u>
			400.0
	(iv)	<u>Capsule 2</u>	<u>mg/capsule</u>
25		'Compound X'	29.6
		Lactose	331.4
		Sodium Lauryl Sulphate	<u>1.0</u>
			362.0
30	(v)	<u>Injection 1 (1mg/mL)</u>	<u>mg/mL</u>
		'Compound X' (free acid form)	1.0

-9-

	Dibasic sodium phosphate	12.0
	Monobasic sodium phosphate	0.7
	Sodium chloride	4.5
	1.0 N Sodium hydroxide solution	q.s
5	(pH adjustment to 7.0-7.5)	
	Water for injection	q.s. ad 1 mL

	(vi) <u>Injection 2 (10 mg/mL)</u>	<u>mg/mL</u>
	'Compound X' (free acid form)	10.0
10	Monobasic sodium phosphate	0.3
	Dibasic sodium phosphate	1.1
	Polyethylene glycol 400	200.0
	0.1 N Sodium hydroxide solution	q.s.
	(pH adjustment to 7.0-7.5)	
15	Water for injection	q.s. ad 1 mL

	(vii) <u>Aerosol</u>	
	'Compound X'	1g
	HFA 227 or HFA 134A with 5% ethanol	

20

It will be appreciated that the above pharmaceutical compositions may be varied according to well-known pharmaceutical techniques to accommodate differing amounts and types of active ingredient 'Compound X'. The aerosol (vii) may be used in conjunction with a standard, metered dose aerosol dispenser.


CLAIMS

1. The use of an NK2 antagonist for treating or prevention of a condition in a patient in need thereof, comprising the step of administering a therapeutically-effective amount of the NK2 receptor antagonist, wherein the condition is gastric asthma or adverse respiratory events associated with gastroesophageal reflux.

2. A use according to Claim 1 additionally comprising the step of administering a NK1 antagonist.

3. A use according to Claim 1 wherein the NK2 antagonist is also an NK1 antagonist.

4. A method according to any of Claim 1 or 2 wherein the NK2 antagonist has the structure



5. Use of an NK2 receptor antagonist for the manufacture of a medicament for the treatment or prevention of a condition, wherein the condition is gastric asthma or adverse respiratory events associated with gastroesophageal reflux.

6. A use according to any one of Claims 1, 2, 3 or 5 wherein the condition is gastric asthma.

7. A use according to any one of Claims 1, 2, 3 or 5 wherein the condition is adverse respiratory events associated with gastroesophageal reflux.

8. An oral pharmaceutical composition for the treatment of a condition, the composition comprising:

-11-

a therapeutically-effective amount of an NK2 antagonist; and
a diluent or carrier;

wherein the condition is gastric asthma or adverse respiratory events associated with gastroesophageal reflux.

5

9. A composition according to Claim 8 wherein the condition is gastric asthma.

10. A composition according to Claim 8 wherein the condition is adverse respiratory events associated with gastroesophageal reflux.

Fig.1.




Fig.2.

